Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CELC

Celcuity Inc

92.62

Aug 06 • 2:58 PM ET -0.29 (-0.32%)

Healthcare Biotechnology USA Mid NASD

Peers: KYMR CRNX VKTX AXSM BMRN MDGL KRYS INCY KROS NBIX

| Held by: VTI XBI IWM VXF IWO VTWO SCHA QMOM FESM VHT

Scroll to Statements

Index	RUT
Market Cap	4.52B
Enterprise Value	4.45B
Income	-192.89M
Sales	0.00M
Book/sh	1.11
Cash/sh	7.94
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	155
IPO	Sep 20, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	83.67
P/C	11.67
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.31
Current Ratio	12.31
Debt/Eq	6.04
LT Debt/Eq	6.04
Option/Short	Yes / Yes

EPS (ttm)	-3.90
EPS next Y	-0.50
EPS next Q	-1.16
EPS this Y	-11.23%
EPS next Y	88.02%
EPS next 5Y	-
EPS past 3/5Y	-13.08% -32.62%
Sales past 3/5Y	- -
EPS Y/Y TTM	-28.74%
Sales Y/Y TTM	-
EPS Q/Q	-12.91%
Sales Q/Q	-
Earnings	May 14 AMC
EPS/Sales Surpr.	6.73% -100.00%

Insider Own	20.21%
Insider Trans	-24.14%
Inst Own	83.31%
Inst Trans	-6.10%
ROA	-61.40%
ROE	-275.17%
ROIC	-51.17%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.83%
SMA50	-4.26%
SMA200	-11.40%
Trades

Shs Outstand	48.35M
Shs Float	38.91M
Short Float	28.66%
Short Ratio	7.11
Short Interest	11.15M
52W High	151.02 -38.67%
52W Low	42.38 118.56%
Volatility	4.85% 6.47%
ATR (14)	5.66
RSI (14)	49.29
Beta	0.20
Rel Volume	0.22
Avg Volume	1.57M
Volume	286,308

Perf Week	5.69%
Perf Month	-14.94%
Perf Quarter	-33.57%
Perf Half Y	-13.91%
Perf YTD	-7.13%
Perf Year	109.61%
Perf 3Y	785.52%
Perf 5Y	344.24%
Perf 10Y	-
Recom	1.00
Target Price	163.55
Prev Close	92.92
Price	92.62
Change	-0.32%

Date	Action	Analyst	Rating Change	Price Target Change
May-04-26	Upgrade	H.C. Wainwright	Neutral → Buy	$165
Apr-27-26	Initiated	Citizens	Mkt Outperform	$150
Dec-12-25	Initiated	Wells Fargo	Overweight	$126
Nov-18-25	Initiated	Wolfe Research	Outperform	$110
Nov-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-22-25	Initiated	Guggenheim	Buy	$110
Jul-01-25	Resumed	Stifel	Buy	$30
Jul-22-24	Initiated	Leerink Partners	Outperform	$29
Feb-22-24	Initiated	Stifel	Buy	$40
Dec-08-23	Initiated	H.C. Wainwright	Buy	$27
Oct-08-21	Initiated	Canaccord Genuity	Buy	$50
Sep-07-21	Initiated	Jefferies	Buy	$48
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy	$50
Jan-28-21	Reiterated	H.C. Wainwright	Buy	$14 → $18
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$11 → $14
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy	$36

Show Previous Ratings

Today 08:34AM	Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-30-26 08:30AM	Newly FDA-Approved REVTORPYK (gedatolisib) Included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer (GlobeNewswire) +5.26%
Jul-15-26 10:29AM	Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits (Investor's Business Daily) -17.60%
09:03AM	Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval (Reuters)
08:18AM	Celcuity gains FDA approval for closely watched breast cancer drug (BioPharma Dive)
05:24PM	Loading…
Jul-14-26 05:24PM	CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug (Stocktwits) +6.99%
04:53PM	Celcuity Announces FDA Approval of REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer (GlobeNewswire)
Jun-19-26 08:24AM	QURE Was Just the Beginning: 5 Biotech Catalysts Im Watching Now (InvestorPlace)
Jun-03-26 10:13PM	Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032 (GlobeNewswire)
07:19AM	Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 (GlobeNewswire)
Jun-02-26 04:56PM	CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results Whats Driving The Selloff? (Stocktwits) -25.65%
11:52AM	Celcuity breast cancer drug misses lofty expectations in ASCO-spotlighted trial (BioPharma Dive)
09:40AM	Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC) (InvestorsHub)
08:25AM	Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
08:03AM	Will Celcuity Rocket On Its Newest Approach To Breast Cancer Treatment (Investor's Business Daily)
08:30AM	Loading…
Jun-01-26 08:30AM	Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026 (GlobeNewswire) -7.47%
May-28-26 08:30AM	Celcuity To Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-26 01:02AM	Celcuity Inc (CELC) Q1 2026 Earnings Call Highlights: Promising Clinical Trials and Strategic ... (GuruFocus.com)
May-14-26 04:01PM	Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +8.23%
07:30AM	Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients (GlobeNewswire)
May-07-26 08:00AM	Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call (GlobeNewswire) -6.26%
May-04-26 09:43AM	AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls (The Fly) +15.38%
08:23AM	Celcuity strengthens case for ASCO-spotlighted breast cancer drug (BioPharma Dive)
May-01-26 05:03PM	Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort (GlobeNewswire)
Mar-26-26 08:30AM	Celcuity Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-25-26 11:02PM	Celcuity Inc (CELC) Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug ... (GuruFocus.com) +8.05%
04:01PM	Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-26 08:00AM	Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Mar-09-26 05:42PM	Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology (GlobeNewswire)
Mar-07-26 09:04PM	Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference (MarketBeat)
04:01PM	Loading…
Feb-25-26 04:01PM	Celcuity To Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-13-26 09:40AM	Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-12-26 04:05PM	Celcuity Appoints Charles Romp to its Board of Directors (GlobeNewswire)
Feb-11-26 11:42PM	Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference (MarketBeat)
Feb-04-26 07:05AM	Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-02-26 09:33AM	Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances (Insider Monkey)
Jan-27-26 09:40AM	Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-20-26 07:30AM	Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (GlobeNewswire)
Jan-11-26 12:59AM	Wells Fargo Initiates Coverage On Celcuity Inc. (CELC) (Insider Monkey)
Jan-06-26 11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-11-25 08:24PM	Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank (Zacks)
02:35PM	Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-03-25 04:43PM	3 Stocks You'll Wish You Bought Before 2026 (MarketBeat) +5.87%
Nov-26-25 04:05PM	Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
07:05AM	Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-23-25 07:02AM	Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View (Insider Monkey)
Nov-18-25 09:35AM	Block upgraded, Dell downgraded: Wall Streets top analyst calls (TipRanks)
Nov-17-25 04:05PM	Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (GlobeNewswire)
09:34AM	Block upgraded, Dell downgraded: Wall Street's top analyst calls (The Fly)
Nov-13-25 12:01AM	Celcuity Inc (CELC) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-12-25 04:01PM	Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.56%
Nov-06-25 10:08AM	Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. (Investor's Business Daily)
10:03AM	Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year. (Investor's Business Daily)
Nov-05-25 07:05AM	Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Nov-04-25 07:05AM	Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference (GlobeNewswire)
Nov-03-25 05:22AM	ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer (Clinical Trials Arena)
Oct-21-25 12:55PM	Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result (Insider Monkey) -7.20%
Oct-20-25 04:13PM	Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily) +35.84%
10:02AM	Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily)
Oct-18-25 04:30AM	Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
04:30AM	Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial (GlobeNewswire)
04:30AM	Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC") (GlobeNewswire)
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire)
Sep-30-25 12:47PM	Celcuity Inc. (CELC)'s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review (Insider Monkey) -5.13%
Sep-22-25 09:15AM	Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Sep-09-25 04:01PM	Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance (GlobeNewswire) -7.96%
Aug-27-25 04:05PM	Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program (GlobeNewswire) +9.29%
Aug-15-25 03:24AM	Celcuity Inc (CELC) Q2 2025 Earnings Call Highlights: Navigating Losses and Strategic Advances (GuruFocus.com)
Aug-14-25 04:01PM	Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-30-25 06:30AM	Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire)
02:15PM	Up 215% YTD, Should You Grab This Growth Stock Before Its Too Late? (Barchart)
09:56AM	Relay Therapeutics has positive read from Celcuity data, says Barclays (TipRanks)
09:43AM	Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial (Insider Monkey)
Jul-28-25 04:02PM	Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock (GlobeNewswire) +167.18%
02:09PM	Celcuity stock rallies on Phase III breast cancer trial progress (Clinical Trials Arena)
11:55AM	Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More (Investopedia)
10:09AM	Celcuity Stock Triples on Positive Breast Cancer Treatment Study (Investopedia)
09:42AM	Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer (Benzinga)
08:15AM	Celcuity shares triple on late-stage results for breast cancer therapy (BioPharma Dive)
07:00AM	Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial (GlobeNewswire)
Jul-25-25 04:05PM	Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-24-25 04:01PM	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-14-25 07:05AM	Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 (GlobeNewswire)
Jun-30-25 07:05AM	Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib (GlobeNewswire) +6.46%
May-21-25 07:05AM	Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences (GlobeNewswire)
May-15-25 09:56AM	Q1 2025 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Celcuity Inc (CELC) Q1 2025 Earnings Call Highlights: Navigating Increased Losses and Strategic ... (GuruFocus.com)
May-14-25 04:01PM	Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Apr-01-25 08:41AM	Q4 2024 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -8.11%
07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
03:03AM	Celcuity Inc (CELC) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 10:50PM	Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-25 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:05AM	Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences (GlobeNewswire) -8.99%

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Co-FounderMr. Brian F. Sullivan

Co-FounderDr. Lance G. Laing Ph.D.

Chief Financial OfficerMs. Vicky Hahne CPA

Head of Investor Relations & Corporate CommunicationsMs. Jodi Sievers

General CounselMr. Brent Eilefson

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	Former 10% owner	Jul 14 '26	Sale	102.50	3,100,000	317,750,000	442,940	Jul 16 05:42 PM
667, L.P.	Former Affiliate	Jul 14 '26	Proposed Sale	102.50	261,368	26,790,220		Jul 14 09:45 PM
Baker Brothers Life Sciences,	Former Affiliate	Jul 14 '26	Proposed Sale	102.50	2,838,632	290,959,780		Jul 14 09:43 PM
Laing Lance G.	Chief Science Officer	Jun 02 '26	Option Exercise	9.89	1,000	9,890	1,251,000	Jun 04 04:52 PM
Dalvey David	Director	May 04 '26	Sale	140.68	25,000	3,517,000	65,000	May 06 04:31 PM
Buller Richard E	Director	May 04 '26	Option Exercise	5.10	9,000	45,900	15,760	May 06 04:30 PM
Buller Richard E	Director	May 04 '26	Sale	140.46	9,000	1,264,181	6,760	May 06 04:30 PM
Buller Richard E	Director	May 04 '26	Proposed Sale	140.46	6,000	842,788		May 04 05:39 PM
Dalvey David	Director	May 04 '26	Proposed Sale	140.68	25,000	3,517,000		May 04 02:18 PM
Buller Richard E	Director	Mar 31 '26	Option Exercise	5.10	3,000	15,300	9,760	Apr 02 04:05 PM
Buller Richard E	Director	Mar 31 '26	Sale	110.27	3,000	330,804	6,760	Apr 02 04:05 PM
Buller Richard E	Director	Mar 31 '26	Proposed Sale	110.27	6,000	661,607		Mar 31 04:38 PM
Dalvey David	Director	Jan 27 '26	Sale	120.03	20,000	2,400,538	90,000	Jan 29 04:31 PM
Dalvey David	Director	Jan 27 '26	Proposed Sale	120.03	20,000	2,400,538		Jan 27 12:21 PM
Buller Richard E	Director	Dec 05 '25	Option Exercise	5.50	3,000	16,500	9,760	Dec 09 04:23 PM
Buller Richard E	Director	Dec 05 '25	Sale	105.69	3,000	317,070	6,760	Dec 09 04:23 PM
Furcht Leo	Director	Dec 04 '25	Option Exercise	7.60	250	1,900	11,000	Dec 08 04:30 PM
Buller Richard E	Director	Dec 05 '25	Proposed Sale	105.68	3,000	317,040		Dec 05 05:31 PM
Buller Richard E	Director	Dec 01 '25	Option Exercise	14.83	1,100	16,313	8,360	Dec 03 04:09 PM
Buller Richard E	Director	Dec 01 '25	Sale	98.13	1,100	107,948	7,260	Dec 03 04:09 PM
Buller Richard E	Director	Dec 01 '25	Proposed Sale	98.13	1,100	107,943		Dec 01 05:46 PM
Dalvey David	Director	Nov 21 '25	Sale	100.00	15,000	1,500,016	110,000	Nov 24 04:07 PM
Buller Richard E	Director	Nov 20 '25	Option Exercise	14.83	3,900	57,837	11,160	Nov 21 04:14 PM
Buller Richard E	Director	Nov 20 '25	Sale	96.73	3,900	377,255	7,260	Nov 21 04:14 PM
Dalvey David	Director	Nov 21 '25	Proposed Sale	100.00	15,000	1,500,016		Nov 21 01:41 PM
Buller Richard E	Director	Nov 20 '25	Proposed Sale	96.73	3,900	377,255		Nov 20 04:33 PM
BAKER BROS. ADVISORS LP	10% Owner	Sep 08 '25	Buy	56.27	170,100	9,571,319	7,211,484	Sep 10 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CELC

Celcuity Inc

Upgrade your Finviz experience